📰 Marek Ciszewski News
Marek Ciszewski News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Marek Ciszewski. Real-time updates on events, politics, business and more.
September 25, 2023
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL – – No...
September 23, 2023
REDWOOD CITY, Calif., Sept. 22, 2023 -- Coherus BioSciences, Inc. , today announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted...
September 8, 2023
Coherus Completes Surface Oncology Acquisition - Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance ...
September 8, 2023
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
August 22, 2023
REDWOOD CITY, Calif., Aug. 22, 2023 -- Coherus BioSciences, Inc. , today announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options...
August 22, 2023
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...
August 4, 2023
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
August 2, 2023
02.08.2023 - – Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA autoinjector launched in late May, and YUSIMRY launched in July –– Planned merger with Surface Oncology ...
July 26, 2023
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on
July 21, 2023
REDWOOD CITY, Calif., July 21, 2023 -- Coherus BioSciences, Inc. , today announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to...